Clinical Trial

IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome

Study acronym: OPTION2
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The OPTION2 trial (randomized controlled trial of IndObufen versus asPirin after coronary drug-eluting stent implantaTION in elderly patients with acute coronary syndrome) was designed to compare the 1-year clinical efficacy and safety of indobufen-based dual antiplatelet therapy (DAPT) (indobufen 100mg bid plus ticagrelor 90mg bid) or conventional DAPT (aspirin 100mg qd plus ticagrelor 90mg bid) in acute coronary syndrome (ACS) patients aged over 65 years old undergoing coronary drug-eluting stent (DES) implantation.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-06-08; most recent amendment 2026-03-11.
Status change: Not Yet Recruiting → Recruiting 2026-02-25
Trial Details
NCT Number NCT06451198
Lead Sponsor Shanghai Zhongshan Hospital
Conditions Coronary Artery Disease, Antiplatelet Drugs
Enrollment 2,846 participants
Start Date 2025-05-19
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-03-12